ClinicaliQ Trial Snapshot
- Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Active Not Recruiting • Phase III • Cardiology / Cardiovascular • NCT04023552.
- Pelacarsen reduced heart attacks and strokes in patients with heart disease and high lipoprotein(a) levels.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a) Conditions: Cardiovascular Disease and Lipoprotein(a) Interventions: TQJ230, Placebo Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 8323 participants